Tembexa FDA Approval History
Last updated by Judith Stewart, BPharm on June 8, 2021.
FDA Approved: Yes (First approved June 4, 2021)
Brand name: Tembexa
Generic name: brincidofovir
Dosage form: Tablets and Oral Suspension
Company: Chimerix, Inc.
Treatment for: Smallpox
Tembexa (brincidofovir) is a nucleotide analog broad-spectrum antiviral indicated for use as a medical countermeasure for smallpox.
- Smallpox is a highly contagious disease caused by the variola virus, which belongs to the orthopoxvirus family of viruses. Tembexa inhibits orthopoxvirus replication by inhibiting viral DNA polymerase-mediated synthesis of viral DNA.
- Tembexa is administered once weekly for 2 doses, on Days 1 and 8.
- The Tembexa product label carries a boxed warning for increased risk for mortality when used for a duration longer than at the recommended dosage.
- Common adverse reactions include diarrhea, nausea, vomiting, and abdominal pain.
Development timeline for Tembexa
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
